A significant amount of secondary sources, directories, and databases were used in this market research study in order to locate and gather data relevant to this technical, financial, and market-oriented analysis of the worldwide biomarkers market. In order to gather and validate crucial qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were carried out with a variety of primary respondents, including important industry participants, subject-matter experts (SMEs), C-level executives of significant market players, and industry consultants, among other experts. To get the ultimate market size, the worldwide biomarkers market's sizeowhich was approximated using a variety of secondary research techniquesowas triangulated with data from primary research.
An immunoassay is a biochemistry-based test used to determine if an analyte is present or concentrated. A big protein or antibody that is created as a result of an infection can be an analyte. Immunoassays are now widely used and recognised laboratory protocols. They deliver exact and accurate results fast and effortlessly. The main applications of this approach are in food testing, drug discovery, clinical diagnostics, and drug monitoring.
The market was divided into a number of segments and sub-segments once the overall market size was determined utilising the market size estimation procedures. Data triangulation and market breakdown processes were used when appropriate to finish the entire market engineering process and obtain the precise statistics of each market segment and subsegment. By examining numerous variables and patterns from the immunoassays industry's supply and demand sides, the data was triangulated.
Immunoassay Market based on Technology:
• ELISA
• Fluorescence
• Colorimetric
• Chemiluminescence
• Rapid Test
• Western Blot
• ELISPOT
• PCR
Immunoassay Market based on Product & Service:
• Reagents & Kits
• Analyzers
• Software Services
Immunoassay Market based on Application:
• Infectious Disease
• Endocrinology
• Cardiology
• Oncology
• Hematology
Immunoassay Market based on End User:
• Hospitals
• Clinical Laboratories
• Blood Banks
• Academic Research Centers
• Pharmaceutical Companies
• Biotechnology Companies
• Others
Immunoassay Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The market for immunoassay has expanded significantly as a result of technology developments. For quicker testing and outcomes, automated laboratory apparatus has been designed. Labour and space requirements are decreased and laboratory efficiency is increased by automation. Because some players provide small, portable automated laboratory systems and point-of-care testing, the industry is growing quickly as a result.
Research laboratories, especially biotechnology labs, should catch up with their counterparts in diagnostics in terms of automated immunoassay implementation, and they should also become more familiar with the development of diagnostic apparatus. Every industry, including healthcare, is becoming more automated. Automated immunoassays, for example, offer increased assay transfer, reproducibility, and throughput.
Reduction in time and operator dependence on unpredictability are the two benefits of this method. In the US, Siemens Healthcare Diagnostic, for example, provides five completely automated immunoassay platforms.
In 2022, the immunoassay market was dominated by the kit and reagent category, which held a market share of over 61%. During the projected period, the sector is anticipated to lead the market. There is a growing need for immunoassay kits and reagents for diagnostic applications due to the rising incidence of autoimmune and infectious disorders. Additionally, immunoassay kit approval and distribution are anticipated to support segment expansion.
In 2022, the immunoassay market was dominated by the ELISA category, which held a market share of over 61%. This method has several advantages over immunoelectrophoretic and immunodiffusion, such as antiserum analysis, faster test periods, and qualitative and qualitative results.
The rising incidence of cancer cases around the world is the main reason boosting the immunoassay market over the predicted period. The International Agency for Research on Cancer projected that there will be over 18.2 million new cases of cancer worldwide in 2020, and that the disease will cause over 10 million deaths. Therefore, it is anticipated that a rise in cancer incidence will increase the use of immunoassays.
The immunoassay market is divided into end-user segments based on the following: blood banks, clinical labs, pharmaceutical & biotechnology firms, hospitals & clinics, research & academic laboratories, CROs, and home care settings. With a 31% market share in 2022, the hospital & clinical segment will have a dominant position in the immunoassay industry. The hospital segment is growing quickly as a result of the rise in hospital numbers.
• This report illustrates the most vital attributes of the Immunoassay Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Immunoassay Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Biomarkers Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Immunoassay Market.
Table of Contents 1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Product Type: Market Size & Analysis 5.1. Overview 5.2. Consumables 5.3. Services 5.4. Software 6. Technology: Market Size & Analysis 6.1. Overview 6.2. Safety Biomarkers 6.3. Efficacy Biomarkers 6.4. Predictive Biomarkers 6.5. Surrogate Biomarkers 6.6. Pharmacodynamics Biomarkers 6.7. Prognostic Biomarkers 6.8. Validation Biomarkers 7. Product & Service: Market Size & Analysis 7.1. Overview 7.2. Safety Biomarkers 7.3. Efficacy Biomarkers 7.4. Predictive Biomarkers 7.5. Surrogate Biomarkers 7.6. Pharmacodynamics Biomarkers 7.7. Prognostic Biomarkers 7.8. Validation Biomarkers 8. Application: Market Size & Analysis 8.1. Overview 8.2. ELISA 8.3. Fluorescence 8.4. Colorimetric 8.5. Chemiluminescence 8.6. Rapid Test 8.7. Western Blot 8.8. ELISPOT 8.9. PCR 9. End user: Market Size & Analysis 9.1. Overview 9.2. Hospitals 9.3. Clinical Laboratories 9.4. Blood Banks 9.5. Academic Research Centers 9.6. Pharmaceutical Companies 9.7. Biotechnology Companies 9.8. Others 10. Geography: Market Size & Analysis 10.1. Overview 10.2. North America (U.S., Mexico, Canada) 10.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 10.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 10.5. Latin America (Brazil, Argentina) 10.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 11. Competitive Landscape 11.1. Competitor Comparison Analysis 11.2. Market Developments 11.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 11.2.2. Product Launches and execution 12. Vendor Profiles 12.1. Siemens Healthineers 12.1.1. Overview 12.1.2. Financial Overview 12.1.3. Product Offerings 12.1.4. Developments 12.1.5. Business Strategy 12.2. bioM?(C)rieux SA 12.2.1. Overview 12.2.2. Financial Overview 12.2.3. Product Offerings 12.2.4. Developments 12.2.5. Business Strategy 12.3. Abbott Laboratories 12.3.1. Overview 12.3.2. Financial Overview 12.3.3. Product Offerings 12.3.4. Developments 12.3.5. Business Strategy 12.4. Danaher Corporation (Beckman Coulter) 12.4.1. Overview 12.4.2. Financial Overview 12.4.3. Product Offerings 12.4.4. Developments 12.4.5. Business Strategy 12.5. Quidel Corporation 12.5.1. Overview 12.5.2. Financial Overview 12.5.3. Product Offerings 12.5.4. Developments 12.5.5. Business Strategy 12.6. Ortho Clinical Diagnostics 12.6.1. Overview 12.6.2. Financial Overview 12.6.3. Product Offerings 12.6.4. Developments 12.6.5. Business Strategy 12.7. Sysmex Corporation 12.7.1. Overview 12.7.2. Financial Overview 12.7.3. Product Offerings 12.7.4. Developments 12.7.5. Business Strategy 12.8. Bio-Rad Laboratories, Inc. 12.8.1. Overview 12.8.2. Financial Overview 12.8.3. Product Offerings 12.8.4. Developments 12.8.5. Business Strategy 12.9. F. Hoffmann-La Roche AG 12.9.1. Overview 12.9.2. Financial Overview 12.9.3. Product Offerings 12.9.4. Developments 12.9.5. Business Strategy 12.10. Thermo Fisher Scientific, Inc. 12.10.1. Overview 12.10.2. Financial Overview 12.10.3. Product Offerings 12.10.4. Developments 12.10.5. Business Strategy 13. Analyst Opinion 14. Annexure 14.1. Report Scope 14.2. Market Definitions 14.3. Research Methodology 14.3.1. Data Collation and In-house Estimation 14.3.2. Market Triangulation 14.3.3. Forecasting 14.4. Report Assumptions 14.5. Declarations 14.6. Stakeholders 14.7. Abbreviations
Tables TABLE 1. IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 2. IMMUNOASSAY MARKET VALUE FOR ELISA, BY GEOGRAPHY , 2021-2030 (USD BILLION) TABLE 3. IMMUNOASSAY MARKET VALUE FOR FLUORESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. IMMUNOASSAY MARKET VALUE FOR COLORIMETRIC, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 5. IMMUNOASSAY MARKET VALUE FOR CHEMILUMINESCENCE, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 6. IMMUNOASSAY MARKET VALUE FOR RAPID TEST, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 7. IMMUNOASSAY MARKET VALUE FOR WESTERN BLOT, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. IMMUNOASSAY MARKET VALUE FOR ELISPOT, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 9. IMMUNOASSAY MARKET VALUE FOR PCR, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION) TABLE 11. IMMUNOASSAY MARKET VALUE FOR REAGENTS & KITS, 2021-2030 (USD BILLION) TABLE 12. IMMUNOASSAY MARKET VALUE FOR ANALYZERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 13. IMMUNOASSAY MARKET VALUE FOR SOFTWARE SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 14. IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 15. IMMUNOASSAY MARKET VALUE FOR INFECTIOUS DISEASE, 2021-2030 (USD BILLION) TABLE 16. IMMUNOASSAY MARKET VALUE FOR ENDOCRINOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 17. IMMUNOASSAY MARKET VALUE FOR CARDIOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 18. IMMUNOASSAY MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 19. IMMUNOASSAY MARKET VALUE FOR HEMATOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 20. IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 21. IMMUNOASSAY MARKET VALUE FOR HOSPITALS, 2021-2030 (USD BILLION) TABLE 22. IMMUNOASSAY MARKET VALUE FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 23. IMMUNOASSAY MARKET VALUE FOR BLOOD BANKS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 24. IMMUNOASSAY MARKET VALUE FOR ACADEMIC RESEARCH CENTERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 25. IMMUNOASSAY MARKET VALUE FOR PHARMACEUTICAL COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 26. IMMUNOASSAY MARKET VALUE FOR BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 27. IMMUNOASSAY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 28. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 29. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 30. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 31. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT & SERVICE, 2021-2030 (USD BILLION) TABLE 32. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 33. NORTH AMERICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 34. U.S IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 35. U.S IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 36. U.S IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 37. U.S IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 38. CANADA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 39. CANADA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 40. CANADA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 41. CANADA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 42. MEXICO IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 43. MEXICO IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 44. MEXICO IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 45. MEXICO IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 46. EUROPE IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 47. EUROPE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 48. EUROPE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 49. EUROPE IMMUNOASSAY MARKET VALUE, END USE INDUSTRIES, 2021-2030 (USD BILLION) TABLE 50. EUROPE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 51. GERMANY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 52. GERMANY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 53. GERMANY IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 54. GERMANY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 55. U.K IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 56. U.K IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 57. U.K IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 58. U.K IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 59. FRANCE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 60. FRANCE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 61. FRANCE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 62. FRANCE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 63. ITALY IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 64. ITALY IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 65. ITALY IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 66. ITALY IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 67. SPAIN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 68. SPAIN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 69. SPAIN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 70. SPAIN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 71. ROE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 72. ROE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 73. ROE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 74. ROE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 75. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 76. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 77. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 78. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 79. ASIA PACIFIC IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 80. CHINA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 81. CHINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 82. CHINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 83. CHINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 84. INDIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 85. INDIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 86. INDIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 87. INDIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 88. JAPAN IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 89. JAPAN IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 90. JAPAN IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 91. JAPAN IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 92. REST OF APAC IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 93. REST OF APAC IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 94. REST OF APAC IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 95. REST OF APAC IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 96. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 97. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 98. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 99. LATIN AMERICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 100. BRAZIL IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 101. BRAZIL IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 102. BRAZIL IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 103. BRAZIL IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 104. ARGENTINA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 105. ARGENTINA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 106. ARGENTINA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 107. ARGENTINA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 108. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 109. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 110. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 111. MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 112. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 113. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 114. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 115. SAUDI ARABIA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 116. UAE IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 117. UAE IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 118. UAE IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 119. UAE IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 120. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION) TABLE 121. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY TECHNOLOGY, 2021-2030 (USD BILLION) TABLE 122. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION) TABLE 123. REST OF MIDDLE EAST AND AFRICA IMMUNOASSAY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION) TABLE 124. SIEMENS HEALTHINEERS: FINANCIALS TABLE 125. SIEMENS HEALTHINEERS: PRODUCTS & SERVICES TABLE 126. SIEMENS HEALTHINEERS: RECENT DEVELOPMENTS TABLE 127. BIOM??RIEUX SA: FINANCIALS TABLE 128. BIOM??RIEUX SA: PRODUCTS & SERVICES TABLE 129. BIOM??RIEUX SA: RECENT DEVELOPMENTS TABLE 130. ABBOTT LABORATORIES: FINANCIALS TABLE 131. ABBOTT LABORATORIES: PRODUCTS & SERVICES TABLE 132. ABBOTT LABORATORIES: RECENT DEVELOPMENTS TABLE 133. DANAHER CORPORATION (BECKMAN COULTER).: FINANCIALS TABLE 134. DANAHER CORPORATION (BECKMAN COULTER).: PRODUCTS & SERVICES TABLE 135. DANAHER CORPORATION (BECKMAN COULTER).: RECENT DEVELOPMENTS TABLE 136. QUIDEL CORPORATION: FINANCIALS TABLE 137. QUIDEL CORPORATION: PRODUCTS & SERVICES TABLE 138. QUIDEL CORPORATION: RECENT DEVELOPMENTS TABLE 139. ORTHO CLINICAL DIAGNOSTICS: FINANCIALS TABLE 140. ORTHO CLINICAL DIAGNOSTICS: PRODUCTS & SERVICES TABLE 141. ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS TABLE 142. SYSMEX CORPORATION: FINANCIALS TABLE 143. SYSMEX CORPORATION: PRODUCTS & SERVICES TABLE 144. SYSMEX CORPORATION: DEVELOPMENTS TABLE 145. BIO-RAD LABORATORIES, INC.: FINANCIALS TABLE 146. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES TABLE 147. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS TABLE 148. F. HOFFMANN-LA ROCHE AG: FINANCIALS TABLE 149. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES TABLE 150. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS TABLE 151. THERMO FISHER SCIENTIFIC, INC.: FINANCIALS TABLE 152. THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES TABLE 153. THERMO FISHER SCIENTIFIC, INC.: RECENT DEVELOPMENTS
Publisher: IHR Insights
Related Reports
- Intrauterine Devices Market By Product Type (Hormonal Intrauterine Device and Copper Intrauterine Device), By Material (Plastic, Copper and Hormonal (Levonorgestrel)), By Age Group (15-24 years, 25-34 years, 35-44 years and Above 44 years), By End-user (Hospital, Gynecology Clinics, Community Health Care Centers and Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
- Arterial Thrombectomy Devices Market By Device Type (Aspiration Thrombectomy Devices, Mechanical Thrombectomy Devices, Rheolytic Thrombectomy Devices, Ultrasound-Assisted Thrombectomy Devices, Laser-Based Thrombectomy Devices, Others), By Application (Peripheral Arterial Disease (PAD), Coronary Artery Disease (CAD), Ischemic Stroke, Renal Artery Thrombosis, Acute limb Ischemia, Others), By End-user (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Academic and Research Institutions), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
- Global Operating Room Infection Control Consumable Competitive Landscape Professional Research Report 2024
- Global Oral Fluid Drug Test System Competitive Landscape Professional Research Report 2024
- Global Orthopaedics Competitive Landscape Professional Research Report 2024
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support